Compare ACADIA Pharmaceuticals Inc. (ACAD) vs PubMatic Inc (PUBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs PubMatic Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while PubMatic Inc trades at $12.96 (market cap $619.32M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 7.2× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | PUBM | |
|---|---|---|
Market Cap | $4.49B | $619.32M |
Sector | Health | Technology |
52-Week High | $28.06 | $13.83 |
52-Week Low | $20.06 | $6.28 |
Enterprise Value | $3.69B | $516.83M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
PubMatic trades at $13.32, down 1.7% over 24 hours, with a bullish technical signal from moving averages and a consensus price target of $17. The company reported a net loss of $14.46M in 2025 despite revenue of $282.93M, though it has beaten earnings expectations in recent quarters. Recent news highlights partnerships and product launches, such as the Creator Marketplace and AgenticOS integrations, aimed at driving growth in digital advertising.
The outlook is mixed: analyst sentiment is evenly split between Buy and Hold, with potential upside to the price target, but profitability concerns and a high P/E ratio of 132 pose risks. Investors should weigh the company's innovation in AI-driven ad tech against ongoing losses and competitive pressures in the programmatic advertising space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
